CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure

Clinical Trial2017 Aug 22;318(8):713-720.

JOURNAL:JAMA. Article Link

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

Felker GM, Anstrom KJ1, Adams KF et al. Keywords: Natriuretic Peptide–Guided Therapy; RCT; usual care; Hospitalization; Cardiovascular Mortality ; Heart Failure and Reduced Ejection Fraction

FULL TEXT PDF